🇺🇸 Exelon (rivastigmine) in United States
39 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 39
Most-reported reactions
- Fall — 6 reports (15.38%)
- Malaise — 5 reports (12.82%)
- Vomiting — 5 reports (12.82%)
- Confusional State — 4 reports (10.26%)
- Convulsion — 4 reports (10.26%)
- Agitation — 3 reports (7.69%)
- Dizziness — 3 reports (7.69%)
- Drug Interaction — 3 reports (7.69%)
- Dyspnoea — 3 reports (7.69%)
- Loss Of Consciousness — 3 reports (7.69%)
Other Neurology approved in United States
Frequently asked questions
Is Exelon (rivastigmine) approved in United States?
Exelon (rivastigmine) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Exelon (rivastigmine) in United States?
Singapore General Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.